|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 2026 | Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung) | CUPPENS, Kristof; Wiesweg, Marcel; Baas, Paul; MAES, Brigitte; Du Pont, Bert; Ploenes, Till; Theegarten, Dirk; Vanbockrijck, Michel; Aigner, Clemens; Hartemink, Koen; Doerr, Fabian; Bolukbas, Servet; Pat, Karin; Schuler, Martin | Journal Contribution | A1 |
| 2 | 2025 | Phase 1b/2 study evaluating telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with budigalimab in patients (pts) with advanced non-squamous (NSQ) non-small cell lung cancer (NSCLC) with no prior treatment for advanced disease and no actionable genomic alterations | Camidge, David Ross; Girard, Nicolas; Lu, Shun; Gadgeel, Shirish M.; CUPPENS, Kristof; Lee, Se-Hoon; Horinouchi, Hidehito; Kim, Tae Min; Delmonte, Angelo; Pons-Tostivint, Elvire; Jotte, Robert M.; Aanur, Nivedita; Coburn, Han; Jiang, Qi; Jennaro, Theodore S.; Navas, Tony; Li , Yan; Goldman, Jonathan W. | Journal Contribution | M |
| 3 | 2025 | Exhaled Breath Analysis in Patients With Resectable NSCLC Treated With Neoadjuvant Immune Checkpoint Inhibitors | CUPPENS, Kristof; VOLDERS, Pieter-Jan; De Vries, R.; Pat, K.; Verfaillie, S.; MAES, Brigitte; Baas, P. | Journal Contribution | M |
| 4 | 2024 | Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC) | Skoulidis, Ferdinandos; CUPPENS, Kristof; Sacher, Adrian G.; Velcheti, Vamsidhar; Lee , Dae Ho; Lin, Mark T.; Fernando, Tharu M.; Li, Shuai; Bradley, Denise; Crnkovic, Martina Zarak; Mathisen, Michael | Journal Contribution | M |
| 5 | 2024 | Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial | Camidge, D. Ross; Bar, Jair; Horinouchi, Hidehito; Goldman, Jonathan; Moiseenko, Fedor; Filippova, Elena; Cicin, Irfan; Ciuleanu, Tudor; Daaboul, Nathalie; Liu, Chunling; Bradbury, Penelope; Moskovitz, Mor; Katgi, Nuran; Tomasini, Pascale; Zer, Alona; Girard, Nicolas; CUPPENS, Kristof; Han, Ji-Youn; Wu, Shang-Yin; Baijal, Shobhit; Mansfield, Aaron S.; Kuo, Chih-Hsi; Nishino, Kazumi; Lee, Se-Hoon; Planchard, David; Baik, Christina; Li, Martha; Ansell, Peter; Xia, Summer; Bolotin, Ellen; Looman, Jim; Ratajczak, Christine; Lu, Shun | Journal Contribution | A1 |
| 6 | 2024 | The Adenosinergic Pathway in Non-Small Cell Lung Cancer | Van Kerkhove, Olivier; Verfaillie, Saartje; MAES, Brigitte; CUPPENS, Kristof | Journal Contribution | A1 |
| 7 | 2024 | Immune checkpoint inhibition in early-stage non-small cell lung cancer | CUPPENS, Kristof; Du Pont, Bert; Knegjens, Joost; MAES, Brigitte; Baas, Paul | Journal Contribution | A1 |
| 8 | 2024 | Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial | Schuler, Martin; CUPPENS, Kristof; Ploenes, Till; Wiesweg, Marcel; Du Pont, Bert; Hegedus, Balazs; Koester, Johannes; Mairinger, Fabian; Darwiche, Kaid; Paschen, Annette; MAES, Brigitte; Vanbockrijck, Michel; Laehnemann, David; Zhao, Fang; Hautzel, Hubertus; Theegarten, Dirk; Hartemink, Koen; Reis, Henning; Baas, Paul; Schramm, Alexander; Aigner, Clemens | Journal Contribution | A1 |
| 9 | 2024 | Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report | Deraedt, Davien; Verfaillie, Saartje; Wynants, Jokke; CUPPENS, Kristof | Journal Contribution | A2 |
| 10 | 2024 | Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up | CUPPENS, Kristof; Baas, P.; Wiesweg, M.; Du Pont, B.; Ploenes, T.; Theegarten, D.; Aigner, C.; Hartemink, K.; MAES, Brigitte; Pat, K.; Schuler, M. | Journal Contribution | M |
| 11 | 2023 | Sjogren's Syndrome Caused by PD-1 Inhibition in a Lung Cancer Patient | Caeyman, Aaron; Vandekerckhove, Olivia; Pat, Karin; Wynants, Jokke; Weytjens, Karolien; de Wergifosse, Isabelle; CUPPENS, Kristof | Journal Contribution | A1 |
| 12 | 2023 | Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04 | Papadopoulos, K. P.; Bruno, D.; Kitazono, S.; Murakami, S.; Gutierrez, M.; Wakuda, K.; Spira, A.; CUPPENS, Kristof; Lovick, S.; Hepner, A.; Mak, G.; Waqar, S. N. | Journal Contribution | M |
| 13 | 2023 | Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer | Donker, H. C.; CUPPENS, Kristof; FROYEN, Guy; Groen, H. J. M.; Hiltermann, T. J. N.; MAES, Brigitte; Schuuring, E.; Volders, P. -J.; Lunter, G. A.; van Es, B. | Journal Contribution | A1 |
| 14 | 2023 | Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial | Cho, Byoung Chul; Lee, Jong Seok; Wu , Yi-Long; Cicin, Irfan; Dols, Manuel Cobo; Ahn, Myung-Ju; CUPPENS, Kristof; Veillon, Remi; Nadal, Ernest; Dias, Josiane Mourao; Martin, Claudio; Reck, Martin; Garon, Edward B.; Felip, Enriqueta; Paz-Ares, Luis; Mornex, Francoise; Vokes, Everett E.; Adjei, Alex A.; Robinson, Clifford; Sato, Masashi; Vugmeyster, Yulia; Machl, Andreas; Audhuy, Francois; Chaudhary, Surendra; Barlesi, Fabrice | Journal Contribution | A1 |
| 15 | 2023 | The path forward in early-stage lung cancer | CUPPENS, Kristof; Baas, Paul | Journal Contribution | A2 |
| 16 | 2022 | A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung) | Schuler, M. H. H.; CUPPENS, Kristof; Ploenes, T.; Vanbockrijck, M.; Wiesweg, M.; Darwiche, K.; Schramm, A.; MAES, Brigitte; Hegedus, B.; Schildhaus, H-U.; Hautzel, H.; Theegarten, D.; Baas, P.; Hartemink, K.; Du Pont, B.; Aigner, C. | Journal Contribution | M |
| 17 | 2022 | Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC) | Vansteenkiste, J. F.; Demedts, I.; Pons-Tostivint, E.; Biesma, B.; Borm, F.; Colinet, B.; CUPPENS, Kristof; Derijcke, S.; Greillier, L.; Juergens, J.; Moro-Sibilot, D.; Perol, M.; Sebastian, M.; Skrzypski, M.; Theelen, W.; Van De Kerkhove, C.; Collodoro, M.; Plumas, J.; Debruyne, C.; Sibille, A. | Journal Contribution | M |
| 18 | 2022 | Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms | Bar, Jair; Peled, Nir; Schokrpur, Shiruyeh; Dudnik, Elizabeth; Wollner, Mira; Girard, Nicolas; Nana, Frank Aboubakar; Derijcke, Sofie; Kian, Waleed; Patel, Sandip P.; Sorotsky, Hadas Yocheved Gantz; Zer, Alona; Moskovitz, Mor; Metro, Giulio; Rottenberg, Yakir; Calles, Antonio; Hochmair, Maximilian; CUPPENS, Kristof; Decoster, Lynn; Addeo, Alfredo | Journal Contribution | M |
| 19 | 2022 | HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors | CUPPENS, Kristof; Baas, Paul; GEERDENS, Ellen; Cruys, Bert; FROYEN, Guy; Decoster, Lynn; THOMEER, Michiel; MAES, Brigitte | Journal Contribution | A1 |
| 20 | 2022 | Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment | Agbarya, Abed; Shalata, Walid; Addeo, Alfredo; Charpidou, Andriani; CUPPENS, Kristof; Brustugun, Odd Terje; Rajer, Mirjana; Jakopovic, Marco; Marinca, Mihai, V; Pluzanski, Adam; Hiltermann, Jeroen; Araujo, Antonio | Journal Contribution | A1 |
Loading...
5
0
5
0
false